Skip to Content
Merck
  • Glutamate-mediated upregulation of the multidrug resistance protein 2 in porcine and human brain capillaries.

Glutamate-mediated upregulation of the multidrug resistance protein 2 in porcine and human brain capillaries.

The Journal of pharmacology and experimental therapeutics (2014-12-17)
Hiram Luna-Munguia, Josephine D Salvamoser, Bettina Pascher, Tom Pieper, Thekla Getzinger, Manfred Kudernatsch, Gerhard Kluger, Heidrun Potschka
ABSTRACT

As a member of the multidrug-resistance associated protein (MRP) family, MRP2 affects the brain entry of different endogenous and exogenous compounds. Considering the role of this transporter at the blood-brain barrier, the regulation is of particular interest. However, there is limited knowledge regarding the factors that regulate MRP2 in neurologic disease states. Thus, we addressed the hypothesis that MRP2 might be affected by a glutamate-induced signaling pathway that we previously identified as one key mechanism in the regulation of P-glycoprotein. Studies in isolated porcine brain capillaries confirmed that glutamate and N-methyl-d-aspartic acid (NMDA) exposure upregulates expression and function of MPR2. The involvement of the NMDA receptor was further suggested by the fact that the NMDA receptor antagonist MK-801 [(5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine], as well as the NMDA receptor glycine binding site antagonist L-701,324 [7-chloro-4-hydroxy-3-(3-phenoxy)phenyl-2(1H)-quinolinone], prevented the impact of glutamate. A role of cyclooxygenase-2 was indicated by coincubation with the cyclooxygenase-2 inhibitor celecoxib and the cyclooxygenase-1/-2 inhibitor indomethacin, which both efficaciously abolished a glutamate-induced upregulation of MRP2. Translational studies in human capillaries from surgical specimen demonstrated a relevant MRP2 efflux function and indicated an effect of glutamate exposure as well as its prevention by cyclooxygenase-2 inhibition. Taken together the findings provide first evidence for a role of a glutamate-induced NMDA receptor/cyclooxygenase-2 signaling pathway in the regulation of MRP2 expression and function. The response to excessive glutamate concentrations might contribute to overexpression of MRP2, which has been reported in neurologic diseases including epilepsy. The overexpression might have implications for brain access of various compounds including therapeutic drugs.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Cycloheximide, ≥90% (HPLC)
Supelco
Cycloheximide, PESTANAL®, analytical standard
Sigma-Aldrich
Actinomycin D, from Streptomyces sp., ≥95% (HPLC)
Sigma-Aldrich
Indomethacin, meets USP testing specifications
Sigma-Aldrich
Indomethacin, 98.5-100.5% (in accordance with EP)
Sigma-Aldrich
Actinomycin D, from Streptomyces sp., ~98% (HPLC)
Sigma-Aldrich
Cycloheximide, from microbial, ≥94% (TLC)
Sigma-Aldrich
Actinomycin D, from Streptomyces sp., suitable for cell culture, ≥95%
Indomethacin, European Pharmacopoeia (EP) Reference Standard
Supelco
Indomethacin, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Cycloheximide, Biotechnology Performance Certified
USP
Indomethacin, United States Pharmacopeia (USP) Reference Standard
Celecoxib, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
7-chloroquinoline, AldrichCPR
Sigma-Aldrich
SC-560, ≥98% (HPLC)
Sigma-Aldrich
Cycloheximide solution, Ready-Made Solution, microbial, 100 mg/mL in DMSO, Suitable for cell culture
Sigma-Aldrich
N-Methyl-D-aspartic acid, ≥98% (TLC), solid
Millipore
Cycloheximide solution, 0.1%, suitable for microbiology